datopotamab deruxtecan + osimertinib

Datopotamab deruxtecan + osimertinib is an investigational combination therapy for cancer, particularly being studied in non-small cell lung cancer (NSCLC) with EGFR mutations. - **Datopotamab deruxtecan** is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody targeting the tumor-associated antigen Trop-2 linked to a cytotoxic topoisomerase I inhibitor payload (deruxtecan). The ADC binds to Trop-2 on tumor cells, is internalized, and releases the cytotoxic agent inside the cell to induce DNA damage and apoptosis by inhibiting topoisomerase I[1][2][4]. - **Osimertinib** is a third-generation small molecule tyrosine kinase inhibitor that selectively inhibits both EGFR-sensitizing and EGFR T790M resistance mutations. It blocks signaling pathways involved in cell proliferation and survival. The combination aims to target two key mechanisms in NSCLC—Trop-2 expression with datopotamab deruxtecan and mutant EGFR signaling with osimertinib—to potentially overcome resistance mechanisms or enhance antitumor activity.

Brand names

TagrissoDatroway

Other names

datopotamab deruxtecan-dlnk + osimertinib